LLY

1,004.73

-1.24%↓

JNJ

246.64

-0.78%↓

ABBV

233.5

-0.27%↓

NVS

164.14

-1.37%↓

MRK

119.71

-1.31%↓

LLY

1,004.73

-1.24%↓

JNJ

246.64

-0.78%↓

ABBV

233.5

-0.27%↓

NVS

164.14

-1.37%↓

MRK

119.71

-1.31%↓

LLY

1,004.73

-1.24%↓

JNJ

246.64

-0.78%↓

ABBV

233.5

-0.27%↓

NVS

164.14

-1.37%↓

MRK

119.71

-1.31%↓

LLY

1,004.73

-1.24%↓

JNJ

246.64

-0.78%↓

ABBV

233.5

-0.27%↓

NVS

164.14

-1.37%↓

MRK

119.71

-1.31%↓

LLY

1,004.73

-1.24%↓

JNJ

246.64

-0.78%↓

ABBV

233.5

-0.27%↓

NVS

164.14

-1.37%↓

MRK

119.71

-1.31%↓

Начало・Списък с акции・Anavex Life Sciences Corp

Anavex Life Sciences Corp

Затворен

СекторЗдравеопазване

4.68 3.31

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

4.42

Максимум

4.73

Ключови измерители
By Trading Economics
Приходи	4.1M -5.7M
Служители	34
EBITDA	3.1M -6.8M

Препоръки
By TipRanks
Препоръки	Купи
12-месечна прогноза	+351.47% upside

Дивиденти
By Dow Jones
Следващи печалби	12.05.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-3.1M 386M
Предишно отваряне	1.37
Предишно затваряне	4.68

Настроения в новините

By Acuity

50%

155 / 352 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Very Strong Bearish Evidence

8.275 / 9.312 Подкрепа & съпротива

Anavex Life Sciences Corp Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

2.03.2026 г., 23:41 ч. UTC

Пазарно говорене

Значими събития в новините

Nikkei May Decline on Concerns About Energy Prices -- Market Talk

2.03.2026 г., 23:37 ч. UTC

Пазарно говорене

Значими събития в новините

Gold Edges Higher Amid Middle East Conflict -- Market Talk

2.03.2026 г., 23:26 ч. UTC

Значими събития в новините

How the Iran Conflict Could Pressure Consumer Staples Companies -- Barrons.com

2.03.2026 г., 22:41 ч. UTC

Пазарно говорене

Australian Reits Wait on Recovery in Trading Multiples -- Market Talk

2.03.2026 г., 22:32 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

2.03.2026 г., 22:32 ч. UTC

Пазарно говорене

RBA Cautious About Potential for Energy Supply Shocks -- Market Talk

2.03.2026 г., 22:21 ч. UTC

Пазарно говорене

Port of Tauranga's Upgraded Profit View Still Looks Conservative -- Market Talk

2.03.2026 г., 22:11 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

2.03.2026 г., 22:11 ч. UTC

Пазарно говорене

Don't Lose Sight of Bigger Picture With Summerset -- Market Talk

2.03.2026 г., 22:10 ч. UTC

Придобивния, сливания и поглъщания

IAC Is Near Deal to Sell Care.com to Private-Equity Firm -- WSJ

2.03.2026 г., 22:06 ч. UTC

Пазарно говорене

Channel Infrastructure's Dividend Positively Surprises -- Market Talk

2.03.2026 г., 22:00 ч. UTC

Пазарно говорене

Печалби

Global Forex and Fixed Income Roundup: Market Talk

2.03.2026 г., 22:00 ч. UTC

Пазарно говорене

Печалби

Fashion Retailer Hallenstein Glasson Still a Smart Buy -- Market Talk

2.03.2026 г., 21:50 ч. UTC

Пазарно говорене

Значими събития в новините

Energy & Utilities Roundup: Market Talk

2.03.2026 г., 21:50 ч. UTC

Пазарно говорене

Значими събития в новините

Basic Materials Roundup: Market Talk

2.03.2026 г., 21:50 ч. UTC

Пазарно говорене

Health Care Roundup: Market Talk

2.03.2026 г., 21:35 ч. UTC

Придобивния, сливания и поглъщания

AT&T Expects Net Debt-To-Adjusted Ebitda Ratio Will Rise to About 3.2x Following Deal With EchoStar and Decline to About 3x by End of 2026

2.03.2026 г., 21:34 ч. UTC

Придобивния, сливания и поглъщания

AT&T Remains on Track to Achieve Its 2026 and Multi-Yr Fincl Guidance

2.03.2026 г., 21:30 ч. UTC

Придобивния, сливания и поглъщания

Update: AES to Be Taken Private in $33 Billion Deal. Why It's the S&P 500's Worst Stock Today. -- Barrons.com

2.03.2026 г., 21:17 ч. UTC

Значими събития в новините

Bank, Brokerage Stocks Recover Lost Ground After Last Week's Selloff -- Despite Iran Conflict -- Barrons.com

2.03.2026 г., 20:44 ч. UTC

Печалби

Berkshire Stock Falls 5% as Earnings, Abel Letter Fail to Excite Investors -- Barrons.com

2.03.2026 г., 20:43 ч. UTC

Пазарно говорене

Значими събития в новините

Treasury Yields Rise, Dollar Strengthens After Attack on Iran -- Market Talk

2.03.2026 г., 20:28 ч. UTC

Печалби

Strategy Stock Rises. The World's Largest Bitcoin Holder Doubles Down on Its Crypto Bet. -- Barrons.com

2.03.2026 г., 20:25 ч. UTC

Пазарно говорене

Значими събития в новините

U.S. Natural Gas Futures Post Moderate Gains -- Market Talk

2.03.2026 г., 20:24 ч. UTC

Печалби

Berkshire Stock Falls 5% as Earnings, Abel Letter Fail to Excite Investors -- Barrons.com

2.03.2026 г., 20:14 ч. UTC

Придобивния, сливания и поглъщания

Update: AES to Be Taken Private in $33 Billion Deal. Why It's the S&P 500's Worst Stock Today. -- Barrons.com

2.03.2026 г., 20:12 ч. UTC

Значими събития в новините

Palantir Rises on Mideast Conflict. Why It's Moving Like a Defense Stock. -- Barrons.com

2.03.2026 г., 20:08 ч. UTC

Пазарно говорене

Значими събития в новините

Global Forex and Fixed Income Roundup: Market Talk

2.03.2026 г., 20:08 ч. UTC

Пазарно говорене

Значими събития в новините

Higher Oil Prices Could Boost Capex in Canada Energy Patch -- Market Talk

2.03.2026 г., 20:05 ч. UTC

Пазарно говорене

Значими събития в новините

Oil Rises On U.S.-Middle East Conflict, But Settles Off Highs -- Market Talk

Сравнение с други в отрасъла

Ценова промяна

Anavex Life Sciences Corp Прогноза

Ценова цел

By TipRanks

351.47% нагоре

12-месечна прогноза

Среден 20 USD 351.47%

Висок 20 USD

Нисък 20 USD

Според 1 анализатори от Wall Street, предложили 12-месечна ценова цел за Anavex Life Sciences Corp през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

1 ratings

Купи

Задържане

Продай

Според 1 анализатори, дали борсови рейтинги на Anavex Life Sciences Corp през последните 3 месеца.

Техническа оценка

By Trading Central

8.275 / 9.312Подкрепа & съпротива

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

The bullish and bearish events are balanced.

Настроение

By Acuity

155 / 352 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Anavex Life Sciences Corp

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome. The company's drug candidate also comprises ANAVEX 3-71, which is in clinical trial for the treatment of schizophrenia, frontotemporal dementia, and Alzheimer's disease. Its preclinical drug candidates include ANAVEX 1-41 for the treatment of depression, stroke, and neurogenerative disease; ANAVEX 1066 for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.